Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | DRD5 | P21918 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15970151 | 0.82 | METAP1 (0.51) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL7040518 | 0.82 | DRD1 (0.57) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL6642979 | 0.82 | DRD1 (0.57) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL15970374 | 0.79 | METAP1 (0.48) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL1512717 | 0.77 | METAP1 (0.69) | METAP1CYP19A1MAOB | |
| SCHEMBL23835146 | 0.77 | METAP1 (0.73) | METAP1MAPK14DRD2DRD1DRD5 | |
| SCHEMBL30887372 | 0.77 | METAP1 (0.73) | METAP1MAPK14DRD2DRD1DRD5 | |
| SCHEMBL6907774 | 0.77 | DRD1 (0.68) | METAP1DRD2DRD1DRD5DRD3 | |
| SCHEMBL12595448 | 0.77 | — | — | |
| SCHEMBL6903663 | 0.77 | DRD1 (0.68) | METAP1DRD2DRD1DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | METAP1 811/4885MAPK14 837/4885DRD2 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.